PT1155692E - Utilizacao de paclitaxel estabilizado com albumina para a preparacao de um farmaco para o tratamento de tumores solidos e o farmaco assim obtido - Google Patents

Utilizacao de paclitaxel estabilizado com albumina para a preparacao de um farmaco para o tratamento de tumores solidos e o farmaco assim obtido

Info

Publication number
PT1155692E
PT1155692E PT01110509T PT01110509T PT1155692E PT 1155692 E PT1155692 E PT 1155692E PT 01110509 T PT01110509 T PT 01110509T PT 01110509 T PT01110509 T PT 01110509T PT 1155692 E PT1155692 E PT 1155692E
Authority
PT
Portugal
Prior art keywords
pharmacy
albumin
treatment
solid tumors
preparation
Prior art date
Application number
PT01110509T
Other languages
English (en)
Portuguese (pt)
Inventor
Marco Falciani
Original Assignee
Acs Dobfar Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11445079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1155692(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acs Dobfar Spa filed Critical Acs Dobfar Spa
Publication of PT1155692E publication Critical patent/PT1155692E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5169Proteins, e.g. albumin, gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5052Proteins, e.g. albumin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT01110509T 2000-05-18 2001-04-27 Utilizacao de paclitaxel estabilizado com albumina para a preparacao de um farmaco para o tratamento de tumores solidos e o farmaco assim obtido PT1155692E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2000MI001107A ITMI20001107A1 (it) 2000-05-18 2000-05-18 Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel

Publications (1)

Publication Number Publication Date
PT1155692E true PT1155692E (pt) 2004-09-30

Family

ID=11445079

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01110509T PT1155692E (pt) 2000-05-18 2001-04-27 Utilizacao de paclitaxel estabilizado com albumina para a preparacao de um farmaco para o tratamento de tumores solidos e o farmaco assim obtido

Country Status (22)

Country Link
US (1) US6652884B2 (enExample)
EP (1) EP1155692B1 (enExample)
JP (1) JP2001354559A (enExample)
KR (2) KR20010105248A (enExample)
CN (1) CN1198609C (enExample)
AT (1) ATE267594T1 (enExample)
AU (1) AU781517B2 (enExample)
BR (1) BR0102040A (enExample)
CA (1) CA2345482A1 (enExample)
DE (1) DE60103453T2 (enExample)
DK (1) DK1155692T3 (enExample)
ES (1) ES2221874T3 (enExample)
HU (1) HU229909B1 (enExample)
IL (1) IL142674A0 (enExample)
IT (1) ITMI20001107A1 (enExample)
MX (1) MXPA01004980A (enExample)
NO (1) NO330511B1 (enExample)
NZ (1) NZ511201A (enExample)
PT (1) PT1155692E (enExample)
RU (1) RU2270003C2 (enExample)
TR (1) TR200101353A2 (enExample)
ZA (1) ZA200103755B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070092563A1 (en) * 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
SI1585548T1 (sl) 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Sestave in metode odmerjanja farmakoloških sredstev
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
CN1925874B (zh) * 2002-12-09 2014-12-17 阿布拉西斯生物科学有限责任公司 组合物和传递药剂的方法
US20040224019A1 (en) * 2004-03-03 2004-11-11 Adi Shefer Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs
AU2006249235B2 (en) 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
CN103285395A (zh) * 2005-02-18 2013-09-11 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
CN101291658B (zh) 2005-08-31 2014-04-16 阿布拉科斯生物科学有限公司 用于制备稳定性增加的水难溶性药物的组合物和方法
LT3311805T (lt) 2005-08-31 2020-04-27 Abraxis Bioscience, Llc Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir priešmikrobinius agentus
CA2626016A1 (en) * 2005-10-21 2007-06-21 Panacea Biotec Limited Pharmaceutical composition comprising at least one anticancer drug and at least one polymer
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
SI2117520T1 (sl) * 2006-12-14 2019-01-31 Abraxis Bioscience, Llc Zdravljenje raka dojk glede na status hormonskih receptorjev z nano delci, ki zajemajo taksan
CA3201293A1 (en) 2007-03-07 2008-09-12 Abraxis Bioscience, Llc Nanoparticle comprising rapamycin and albumin as anticancer agent
CA2686736A1 (en) * 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Nanoparticle compositions comprising rapamycin for treating pulmonary hypertension
AU2008260447B2 (en) 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
AU2009234127B2 (en) * 2008-04-10 2015-04-30 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
KR101090505B1 (ko) * 2008-12-30 2011-12-06 최은아 난담반을 포함하는 암 예방 및 치료용 조성물
ES2764100T3 (es) 2009-04-15 2020-06-02 Abraxis Bioscience Llc Composiciones de nanopartículas exentas de priones y métodos
EP2552438B1 (en) 2010-03-26 2016-05-11 Abraxis BioScience, LLC Methods of treatment of hepatocellular carcinoma
BR112012024442A2 (pt) 2010-03-29 2017-03-21 Abraxis Bioscience Llc métodos de tratamento de câncer
CA2794147A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma
RU2576609C2 (ru) 2010-06-04 2016-03-10 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечение рака поджелудочной железы
CA2834040C (en) 2011-04-28 2020-01-14 Abraxis Bioscience, Llc Intravascular delivery of nanoparticle compositions and uses thereof
HUE045661T2 (hu) 2011-12-14 2020-01-28 Abraxis Bioscience Llc Polimer segédanyagok alkalmazása részecskék liofilizálásához vagy fagyasztásához
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP2968254B1 (en) 2013-03-12 2020-04-22 Abraxis BioScience, LLC Methods of treating lung cancer
EP2968253A4 (en) * 2013-03-13 2016-11-02 Abraxis Bioscience Llc METHOD FOR TREATING PEDIATRIC SOLID TUMORS
EP2968191B1 (en) 2013-03-14 2021-06-16 Abraxis BioScience, LLC Methods of treating bladder cancer
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
LT3313401T (lt) 2015-06-29 2022-01-10 Abraxis Bioscience, Llc Nanodalelės, apimančios sirolimą ir albuminą, skirtos naudoti epitelioidinių ląstelių navikų gydymui
CN109906088A (zh) 2016-08-26 2019-06-18 奥野哲治 微血管血流减少剂及其应用
TWI660728B (zh) 2018-02-09 2019-06-01 國立交通大學 胺基喹唑啉衍生物及其醫藥組合物與用途
BR112020018910A2 (pt) 2018-03-20 2020-12-29 Abraxis Bioscience, Llc Métodos de tratamento de transtorno do sistema nervoso central através da administração de nanopartículas de um unibidor de mtor e de uma albumina
JP2022553426A (ja) 2019-10-28 2022-12-22 アブラクシス バイオサイエンス, エルエルシー アルブミンおよびラパマイシンの医薬組成物
CN120919082A (zh) * 2025-10-16 2025-11-11 天津医科大学总医院 一种负载蛋白药物的GelMA微球、制备方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2678833B1 (fr) * 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
CN1245156C (zh) 1993-02-22 2006-03-15 美国生物科学有限公司 用于体内传送生物制品的方法及用于该方法的组合物
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
DK1023050T3 (da) * 1997-06-27 2013-10-14 Abraxis Bioscience Llc Nye formuleringer af farmakologiske midler, fremgangsmåder til fremstillingen deraf og fremgangsmåder til anvendelsen deraf
IL141155A0 (en) 1998-07-30 2002-02-10 Human Rt Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin

Also Published As

Publication number Publication date
CN1198609C (zh) 2005-04-27
EP1155692B1 (en) 2004-05-26
US20010046961A1 (en) 2001-11-29
NO330511B1 (no) 2011-05-09
BR0102040A (pt) 2002-03-19
NZ511201A (en) 2002-11-26
NO20012409D0 (no) 2001-05-16
HUP0102039A3 (en) 2002-12-28
HU229909B1 (en) 2014-12-29
AU3876501A (en) 2001-11-22
HK1040368A1 (en) 2002-06-07
KR20080091747A (ko) 2008-10-14
ATE267594T1 (de) 2004-06-15
ITMI20001107A0 (it) 2000-05-18
RU2270003C2 (ru) 2006-02-20
HUP0102039A2 (hu) 2002-05-29
TR200101353A3 (tr) 2001-12-21
TR200101353A2 (tr) 2001-12-21
KR20010105248A (ko) 2001-11-28
ZA200103755B (en) 2001-11-15
HU0102039D0 (en) 2001-07-30
AU781517B2 (en) 2005-05-26
NO20012409L (no) 2001-11-19
EP1155692A1 (en) 2001-11-21
CA2345482A1 (en) 2001-11-18
JP2001354559A (ja) 2001-12-25
ITMI20001107A1 (it) 2001-11-18
DE60103453D1 (de) 2004-07-01
IL142674A0 (en) 2002-03-10
DK1155692T3 (da) 2004-08-09
ES2221874T3 (es) 2005-01-16
US6652884B2 (en) 2003-11-25
MXPA01004980A (es) 2002-08-06
CN1324613A (zh) 2001-12-05
DE60103453T2 (de) 2005-06-23

Similar Documents

Publication Publication Date Title
PT1155692E (pt) Utilizacao de paclitaxel estabilizado com albumina para a preparacao de um farmaco para o tratamento de tumores solidos e o farmaco assim obtido
CY2014008I1 (el) Παραγωγα κιναζολινης, φαρμακα που περιεχουν τις ενωσεις αυτες χρηση αυτων και μεθοδους για την παραγωγη τους
EE200300212A (et) Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks
DE60202677D1 (de) Implantierbare medizinische vorrichtung mit kontrollierter freigabe von gasförmigen mitteln
NO20022970L (no) Hydrogel-drevet medikamentdoseringsform
ATE478840T1 (de) 3-aminoazetidinderivate enthaltende pharmazeutische zusammensetzungen, diese derivate und deren herstellung
EE200200673A (et) Kinasoliini derivaadid kasvajate raviks
NO20053224D0 (no) Patient controlled drug administration device.
CY1106468T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
WO2003080582A3 (de) Fredericamycin-derivate
BR0312573A (pt) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
NO20016304L (no) Erytropoetinkonjugater med polyetylenglykol, fremstilling av slike konjugater, preparater omfattende slike konjugater samt anvendelse av slike konjugater for fremstilling av medikamenter for forebygging eller behandling av sykdom
EE200200201A (et) Trüosiinkinaasi pärssiv ühend, seda sisaldav farmatseutiline kompositsioon ning raviotstarbeline kasutamine.
AR028285A1 (es) Medicamentos intracorporeos para tratamiento fotodinamico de enfermedad
PT1401841E (pt) Derivados substituidos de 1-oxa-2,8-diaza-espiro[4.5]dec-2-eno como medicamentos para o tratamento da dor
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
EE200300311A (et) Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
BRPI0209720A2 (pt) dosagem e embalagem de medicação com liberação controlada
NO20040516L (no) Kombinasjonsterapi for behandling av kreft.
PT1154777E (pt) Medicamento para o tratamento de hipertensao arterial
FI20000780L (fi) Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
NO20033341D0 (no) Metoder for administrering av epothilone-analoger for behandling av kreft
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
EE200200605A (et) Asendatud akrüloüüldistamütsiini derivaadi kasutamine ravimi valmistamiseks, mis on ette nähtud glutatiooni kõrge tasemega seotud kasvajate raviks
PT1385512E (pt) Utilizacao de derivados de piridoindolona para preparacao de medicamentos anticancerigenos